Safety and efficacy of oral factor-Xa inhibitors versus Vitamin K antagonist in patients with non-valvular atrial fibrillation: Meta-analysis of phase II and III randomized controlled trials

International Journal of Cardiology

Volumn 218, Issue , 2016, Pages 235-239

  Garg, Jalaj ^a   Chaudhary, Rahul ^b   Krishnamoorthy, Parasuram ^c   Palaniswamy, Chandrasekar ^d   Shah, Neeraj ^a   Bozorgnia, Babak ^a   Natale, Andrea ^e  

^a LEHIGH VALLEY HOSPITAL   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Einstein Healthcare Network   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e TEXAS CARDIAC ARRHYTHMIA INSTITUTE   (United States)

Author keywords

All cause mortality; Atrial fibrillation; Bleeding; Factor X inhibitors; Stroke

Indexed keywords

ANTIVITAMIN K; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DAREXABAN; EDOXABAN; RIVAROXABAN; WARFARIN; VITAMIN K GROUP;

ALL CAUSE MORTALITY; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EMBOLISM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MORTALITY; NON VALVULAR ATRIAL FIBRILLATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TREATMENT OUTCOME; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPARATIVE STUDY; HEMORRHAGE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ATRIAL FIBRILLATION; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; FACTOR XA INHIBITORS; HEMORRHAGE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VITAMIN K;

EID: 84971276132     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.05.059     Document Type: Article

References (20)

1. S. Colilla, A. Crow, W. Petkun, D.E. Singer, T. Simon, and X. Liu Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population Am. J. Cardiol. 112 8 2013 1142 1147 (Epub 2013/07/09)
2. C.T. January, L.S. Wann, J.S. Alpert, H. Calkins, J.E. Cigarroa, J.C. Cleveland Jr., and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society Circulation 130 23 2014 2071 2104 (Epub 2014/04/01)
3. G. Biondi-Zoccai, V. Malavasi, F. D'Ascenzo, A. Abbate, P. Agostoni, M. Lotrionte, and et al. Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses HSR Proc. Intensive Care Cardiovasc. Anesth. 5 1 2013 40 54 (Epub 2013/06/05)
4. C. Cameron, D. Coyle, T. Richter, S. Kelly, K. Gauthier, S. Steiner, and et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation BMJ Open 4 6 2014 e004301 (Epub 2014/06/04)
5. W. Fu, H. Guo, J. Guo, K. Lin, H. Wang, Y. Zhang, and et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis J. Cardiovasc. Med. (Hagerstown) 15 12 2014 873 879 (Epub 2014/10/12)
6. G.Y. Lip, S.A. Mitchell, X. Liu, L.Z. Liu, H. Phatak, S. Kachroo, and et al. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups Int. J. Cardiol. 204 2016 88 94 (Epub 2015/12/15)
7. P. Verdecchia, F. Angeli, C. Bartolini, V. De Filippo, A. Aita, L. Di Giacomo, and et al. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian meta-analysis approach Expert Opin. Drug Saf. 14 1 2015 7 20 (Epub 2014/10/15)
8. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 361 12 2009 1139 1151 (Epub 2009/09/01)
9. K.M. Bruins Slot, and E. Berge Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation Cochrane Database Syst. Rev. 8 2013 CD008980 (Epub 2013/08/09)
10. D.M. Siegal, J.T. Curnutte, S.J. Connolly, G. Lu, P.B. Conley, B.L. Wiens, and et al. Andexanet alfa for the reversal of factor Xa inhibitor activity N. Engl. J. Med. 373 25 2015 2413 2424 (Epub 2015/11/13)
11. C.B. Granger, J.H. Alexander, J.J. McMurray, R.D. Lopes, E.M. Hylek, M. Hanna, and et al. Apixaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 365 11 2011 981 992 (Epub 2011/08/30)
12. S. Ogawa, Y. Shinohara, and K. Kanmuri Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. The ARISTOTLE-J study Circ. J. 75 8 2011 1852 1859 (Epub 2011/06/15)
13. J.I. Weitz, S.J. Connolly, I. Patel, D. Salazar, S. Rohatagi, J. Mendell, and et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation Thromb. Haemost. 104 3 2010 633 641 (Epub 2010/08/10)
14. R.P. Giugliano, C.T. Ruff, E. Braunwald, S.A. Murphy, S.D. Wiviott, J.L. Halperin, and et al. Edoxaban versus warfarin in patients with atrial fibrillation N. Engl. J. Med. 369 22 2013 2093 2104 (Epub 2013/11/21)
15. N. Chung, H.K. Jeon, L.M. Lien, W.T. Lai, H.F. Tse, W.S. Chung, and et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation Thromb. Haemost. 105 3 2011 535 544 (Epub 2010/12/08)
16. T. Yamashita, Y. Koretsune, M. Yasaka, H. Inoue, Y. Kawai, T. Yamaguchi, and et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation Circ. J. 76 8 2012 1840 1847 (Epub 2012/06/06)
17. S.J. Connolly, J. Eikelboom, P. Dorian, S.H. Hohnloser, D.D. Gretler, U. Sinha, and et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa) Eur. Heart J. 34 20 2013 1498 1505 (Epub 2013/03/15)
18. M. Hori, M. Matsumoto, N. Tanahashi, S. Momomura, S. Uchiyama, S. Goto, and et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study Circ. J. 76 9 2012 2104 2111 (Epub 2012/06/06)
19. M.R. Patel, K.W. Mahaffey, J. Garg, G. Pan, D.E. Singer, W. Hacke, and et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N. Engl. J. Med. 365 10 2011 883 891 (Epub 2011/08/13)
20. G.Y. Lip, J.L. Halperin, P. Petersen, G.M. Rodgers, D. Pall, and R.W. Renfurm A phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2) J. Thromb. Haemost. 13 8 2015 1405 1413 (Epub 2015/06/09)